drugset / Trial / NCT00474045

Efficacy and Safety of Insulin Detemir Versus Neutral Protamine Hagedorn (NPH) Insulin in Pregnant Women With Type 1 Diabetes

NCT00474045 ↗

Phase 3 Completed 470 enrolled Novo Nordisk A/S
RandomizedParallel-groupOpen-labelTreatment

Summary

This trial is conducted in Africa, Europe, North and South America and Oceania. The aim of this trial is to compare the effect and safety on blood glucose control in pregnant women with type 1 diabetes of a modern insulin analogue (insulin detemir) and human insulin (NPH insulin) given as long-acting insulin in combination with a short-acting insulin (insulin aspart).

Timeline

Start
2007-05
Primary completion
2010-08
Completion
2010-08

Outcome

Met primary endpoint

paper IDet was declared noninferior to NPH (FAS, -0.06% [95% CI -0.21 to 0.08]; per protocol, -0.15% [-0.34 to 0.04]). PMID 22851598 ↗

Drugs

EvaluationDrugModalityDoseRoute
Comparator NPH insulin Protein / enzyme biologic — Subcutaneous
Subject insulin detemir Protein / enzyme biologic — Subcutaneous
Background insulin aspart Protein / enzyme biologic — Subcutaneous